두경부 편평상피암(HNSCC) : 시장 전망, 역학, 경쟁 구도, 시장 예측 보고서(2025-2035년)

Head and Neck Squamous Cell Carcinoma (HNSCC) Market Outlook

Thelansis's "Head and Neck Squamous Cell Carcinoma (HNSCC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Head and Neck Squamous Cell Carcinoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Head and Neck Squamous Cell Carcinoma (HNSCC) Overview

Head and Neck Squamous Cell Carcinoma (HNSCC) is a biologically heterogeneous and highly aggressive group of malignancies arising from the mucosal epithelium of the oral cavity, pharynx, and larynx. It represents one of the most prevalent cancers globally and is driven by two primary etiological pathways: chronic exposure to tobacco and alcohol, and infection with high-risk human papillomavirus (HPV).

HPV-positive HNSCC, particularly in the oropharynx, has emerged as a distinct clinical subtype with improved prognosis and greater responsiveness to treatment compared to HPV-negative disease, despite often presenting with advanced nodal involvement. Most patients are diagnosed at a locally advanced stage, requiring multidisciplinary, function-preserving treatment approaches, including surgery, radiation therapy, and platinum-based chemoradiation. However, recurrence rates remain high, with a significant proportion progressing to recurrent or metastatic (R/M) disease.

The treatment paradigm for R/M HNSCC has evolved significantly with the introduction of immune checkpoint inhibitors targeting PD-1, which have become a cornerstone of therapy, either as monotherapy or in combination with chemotherapy. Despite these advances, overall prognosis remains poor, highlighting the need for more effective and durable treatment strategies.

Key Highlights

• In the US, prevalence (survival-adjusted cases) is projected to increase from 404.1K in 2025 to 432.3K by 2035, reflecting steady growth (0.7% CAGR).
• High rates of recurrence and progression to metastatic disease remain a major clinical challenge, with limited long-term survival in advanced stages.
• Increasing adoption of immunotherapy and biomarker-driven treatment approaches is reshaping the therapeutic landscape, particularly in recurrent/metastatic settings.

Market Overview

• The France HNSCC market is projected to grow from $105M in 2025 to $335M by 2035, reflecting strong double-digit growth driven by expanding use of immunotherapies.
• Market expansion is supported by:
• Increased uptake of immune checkpoint inhibitors (PD-1 inhibitors)
• Broader use of combination regimens in advanced disease
• Despite relatively stable patient growth, market value is driven by high-cost oncology therapies and extended treatment duration.
• Future growth will depend on advancements in immuno-oncology, targeted therapies, and personalized treatment strategies to improve survival outcomes.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Fulgent Pharma LLC.
• CSPC Megalith Biopharmaceutical Co., Ltd.
• Gilead Sciences
• Merck Sharp & Dohme LLC
• Sichuan Baili Pharmaceutical Co., Ltd.
• Transgene
• Regeneron Pharmaceuticals
• Inhibrx Biosciences, Inc
• AstraZeneca
• Coherus Oncology, Inc.
• Ipsen
• Radiopharm Theranostics, Ltd
• KaliVir Immunotherapeutics
• IDEAYA Biosciences
• ImmunityBio, Inc.
• Rondo Therapeutics
• AbbVie
• Sutro Biopharma, Inc.
• SystImmune Inc.
• Zumutor Biologics Inc.
• Arcus Biosciences, Inc.
• Normunity AccelCo, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)